

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1.- 27. (Cancelled)

28. (Previously Presented) A method for preventing a ras-activated neoplasm in a subject from developing drug resistance to a chemotherapeutic agent, comprising:

- (a) determining, in a subject having a ras-activated neoplasm, if the ras activated neoplasm includes ras-activated neoplastic cells that are refractory to a chemotherapeutic agent;
- (b) administering to the subject an effective amount of reovirus under conditions which result in infection of the ras-activated neoplasm by the reovirus; and
- (c) administering to the subject an effective amount of the chemotherapeutic agent,

wherein the infection prevents the ras-activated neoplasm from developing drug resistance to the chemotherapeutic agent.

29. - 39. (Cancelled)

40. (Currently Amended) The method of claim ~~27~~ 28 wherein the reovirus is administered in multiple doses prior to administration of the chemotherapeutic agent.

41. - 43. (Cancelled)

44. (Previously Presented) The method of claim 28 wherein the chemotherapeutic agent is selected from the group consisting of 5-fluorouracil, mitomycin C, methotrexate, hydroxyurea,

cyclophosphamide, dacarbazine, mitoxantrone, anthracyclins, carboplatin, cisplatin, taxol, taxotere, tamoxifen, anti-estrogens, and interferons.

45. (Previously Presented) The method of claim 28 wherein the reovirus is a mammalian reovirus.

46. (Previously Presented) The method of claim 45 wherein the mammalian reovirus is a human reovirus.

47. (Previously Presented) The method of claim 46 wherein the human reovirus is a serotype 3 reovirus.

48. (Previously Presented) The method of claim 47 wherein the serotype 3 reovirus is a Dearing strain reovirus.

49. (Previously Presented) The method of claim 28 wherein the reovirus is administered systemically.

50. (Previously Presented) The method of claim 28 wherein the chemotherapeutic agent is cisplatin.

51. (Previously Presented) The method of claim 28 wherein the reovirus administration prevents the ras-activated neoplasm from developing drug resistance to a second chemotherapeutic agent.

52.-55. (Cancelled)

56. (Previously Presented) The method of claim 28, wherein the reovirus is administered prior to administration of the chemotherapeutic agent.

57. (Previously Presented) The method of claim 28, wherein the reovirus and the chemotherapeutic agent are administered concurrently.

58. — 59. (Cancelled)